Sorafenib after RFA in HCC Patients: a Pilot Study

被引：12

作者：

de Stefano, Giorgio ^{[1
]}

Farella, Nunzia ^{[1
]}

Scognamiglio, Umberto ^{[1
]}

Liorre, Giulia ^{[1
]}

Calabria, Giosuele ^{[1
]}

Ascione, Tiziana ^{[1
]}

Giorgio, Antonio ^{[1
]}

Iodice, Valentina ^{[1
]}

机构：

[1] AORN Osped Colli, Intervent Ultrasound Unit Infect Dis 9, Naples, Italy

来源：

HEPATO-GASTROENTEROLOGY | 2015年 / 62卷 / 138期

关键词：

Radiofrequency ablation; Sorafenib; HCC; Combination therapy; RADIOFREQUENCY ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION; HEPATOCELLULAR-CARCINOMA; COMBINATION; INJECTION;

D O I：

10.5754/hge14866

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background/Aims: To investigate the effectiveness and safety of sorafenib after radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). Methodology: 44 intermediate or advanced HCC patients received sorafenib treatment after debulking with RFA therapy. Time to progression (TTP), response rate (RR), duration of sorafenib treatment and adverse effects were evaluated. An explorative comparison was performed with patients treated with sorafenib only. Results: At 12 months, TTP was 10.3 months (range: 1-32). RR was 61% with 2 complete responses, and duration of sorafenib therapy was 10.9 months (1-32). No new safety concerns were reported. With sorafenib only, TTP was 7.2 months (range: 0-38) and RR was 40%, with one complete response; duration of therapy was 7.3 months (0-38). Conclusions: The sequence of RFA and sorafenib appears effective and safe in HCC patients. These findings could support the use of a sequential treatment with RFA and sorafenib in HCC patients.

引用

页码：261 / 263

页数：3

共 19 条

[1] Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma [J].

Bolondi, Luigi ;

Cillo, Umberto ;

Colombo, Massimo ;

Craxi, Antonio ;

Farinati, Fabio ;

Giannini, Edoardo G. ;

Golfieri, Rita ;

Levrero, Massimo ;

Pinna, Antonio Daniele ;

Piscaglia, Fabio ;

Raimondo, Giovanni ;

Trevisani, Franco ;

Bruno, Raffaele ;

Caraceni, Paolo ;

Ciancio, Alessia ;

Coco, Barbara ;

Fraquelli, Mirella ;

Rendina, Maria ;

Squadrito, Giovanni ;

Toniutto, Pierluigi .

DIGESTIVE AND LIVER DISEASE, 2013, 45 (09) :712-723

[2] Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions [J].

Bolondi, Luigi ;

Burroughs, Andrew ;

Dufour, Jean-Francois ;

Galle, Peter R. ;

Mazzaferro, Vincenzo ;

Piscaglia, Fabio ;

Raoul, Jean Luc ;

Sangro, Bruno .

SEMINARS IN LIVER DISEASE, 2012, 32 (04) :348-359

[3] Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma [J].

Boulin, Mathieu ;

Adam, Heloise ;

Guiu, Boris ;

Aho, Ludwig Serge ;

Cercueil, Jean-Pierre ;

Di Martino, Cyrille ;

Fagnoni, Philippe ;

Minello, Anne ;

Jouve, Jean Louis ;

Hillon, Patrick ;

Bedenne, Laurent ;

Lepage, Come .

DIGESTIVE AND LIVER DISEASE, 2014, 46 (04) :358-362

[4] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

[5] Systematic Review of Randomized Trials for Hepatocellular Carcinoma Treated with Percutaneous Ablation Therapies [J].

Cho, Yun Ku ;

Kim, Jae Kyun ;

Kim, Mi Young ;

Rhim, Hyunchul ;

Han, Joon Koo .

HEPATOLOGY, 2009, 49 (02) :453-459

[6]

EMA, 2011, Annex 1. Summary of product characteristics

[7]

European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]

[8] Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis [J].

Germani, Giacomo ;

Pleguezuelo, Maria ;

Gurusamy, Kurinchi ;

Meyer, Tim ;

Isgro, Graziella ;

Burroughs, Andrew Kenneth .

JOURNAL OF HEPATOLOGY, 2010, 52 (03) :380-388

[9] Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy:: Study in mice [J].

Hakime, Antoine ;

Hines-Peralta, Andrew ;

Peddi, Himaja ;

Atkins, Michael B. ;

Sukhatme, Vikas P. ;

Signoretti, Sabina ;

Regan, Meredith ;

Goldberg, S. Nahum .

RADIOLOGY, 2007, 244 (02) :464-470

[10]

Kong J, 2012, PLOS ONE, V7

← 1 2 →